$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
舒尼替尼使胃肠道间质瘤患者受益
2025-10-19 11:44:20
Check Details
舒尼替尼降低胃肠间质瘤患者50%死亡风险
2025-10-19 11:44:20
Check Details
舒尼替尼治疗胃肠间质瘤的数据
2025-10-19 11:44:20
Check Details
瑞格非尼治疗胃肠道间质瘤
2025-10-19 11:44:20
Check Details
瑞戈非尼获批用于治疗胃肠道间质瘤
2025-10-19 11:44:20
Check Details
瑞格非尼治疗胃肠道间质瘤(GIST)患者
2025-10-19 11:44:20
Check Details
舒尼替尼治疗格列卫不耐受的胃肠道间质瘤
2025-10-19 11:44:20
Check Details
舒尼替尼剂量如何调整
2025-10-19 11:44:20
Check Details
瑞格非尼治疗舒尼替尼耐药胃肠道间质瘤患
2025-10-19 11:44:20
Check Details
卡博替尼可抑制胃肠间质瘤肿瘤活性
2025-10-19 11:44:20
Check Details
瑞格非尼治疗胃肠道间质性肿瘤患者
2025-10-19 11:44:20
Check Details
胃肠道基质肿瘤患者可以服用舒尼替尼
2025-10-19 11:44:20
Check Details
1
2
...
6800
6801
6802
6803
6804
6805
6806
...
10233
10234
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Hibsago (Bepirovirsen) Japan Approval: CHB Functional Cure and B-Well Data Essentials
2
FDA Approves Isembyld (apitegromab-mstn), the World’s First Skeletal Muscle-Targeted Therapy for SMA
3
Post-Enzalutamide mCRPC: HRR/PARP, PSMA Radioligand, and Chemotherapy Sequencing
4
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
5
Acalabrutinib in CLL/SLL Survival Expectation: ELEVATE-TN and ASCEND Long-Term PFS, OS
6
Bosutinib for CML: Time to Response, BCR-ABL Monitoring, and Molecular Remission
7
Bedaquiline for Drug-Resistant TB: 24-Week Regimen, Combination Duration, and When to Stop or Extend
8
Acalabrutinib Dosing and Combination Regimens: CLL/SLL, MCL, Safety Adjustments
9
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
10
Bosutinib for Ph+ CML: Indications, Dosing Adjustments, and Hepatic/Renal Safety
11
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
12
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance